Evidence map›Paper›PMID 32180914›Full record

ArticleMediterranean journal of hematology and infectious diseases2020

Discovery of Type 3 von Willebrand Disease in a Cohort of Patients with Suspected Hemophilia A in Côte d'Ivoire.

Adia E Adjambri, Sylvie Bouvier, Roseline N'guessan, Emma N'draman-Donou, Mireille Yayo-Ayé, Marie-France Meledje, Missa L Adjé, Duni Sawadogo

Open access · goldAbstract read
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Adia E AdjambriDepartment of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d'Ivoire.
Sylvie BouvierDepartment of Hematology, Nîmes University Hospital, University of Montpellier, France.
Roseline N'guessanDepartment of Pediatrics, Yopougon University Hospital, Abidjan, Côte d'Ivoire.
Emma N'draman-DonouDepartment of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d'Ivoire.
Mireille Yayo-AyéDepartment of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d'Ivoire.
Marie-France MeledjeHematology Unit, Central Laboratory, Yopougon University Hospital, Abidjan, Côte d'Ivoire.
Missa L AdjéHematology Unit, Central Laboratory, Yopougon University Hospital, Abidjan, Côte d'Ivoire.
Duni SawadogoDepartment of Hematology, Faculty of Pharmacy, Felix Houphouet Boigny University, Abidjan, Côte d'Ivoire.
Centre Hospitalier Universitaire de Yopougon · CIUniversité Félix Houphouët-Boigny · CIUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 3 von Willebrand disease (VWD) is the most severe form of VWD, characterized by a near-total absence of von Willebrand factor (vWF), leading to a massive deficiency in plasmatic factor VIII (FVIII). VWD may be confused with hemophilia A, sometimes leading to misdiagnosis. The purpose of this work was to finalize the biological diagnosis of patients with FVIII activity deficiency in Abidjan in order to guide the best type of management.

methodsWe conducted a cross-sectional descriptive study from June 2018 to April 2019. Forty-nine patients, all of whom had lower FVIII levels or had been referred for a bleeding disorder, were monitored in the clinical hematology service. The pro-coagulant activity of coagulation factors was performed in Abidjan. The assays for von Willebrand antigen and activity were performed at Nîmes University Hospital in France.

resultsThe mean age of patients was 13.8 years (1 - 65) and 86% were Ivorian. FVIII deficiency was discovered during a biological checkup, circumcision or post-traumatic bleeding, in 33%, 31% and 29% respectively. The FVIII deficiency of patients was classified as severe (89.8%), moderate (8.2%) and mild (2%). Only one patient had a quantitative deficiency of von Willebrand factor (vWF: Ag <3%) with undetectable von Willebrand factor activity (vWF: Ac) and an FVIII level <1%.

conclusionsNot all of the congenital deficiency of FVIII are represented by hemophilia A. It was crucial to assess the Willebrand factor of these patients followed in Côte d'Ivoire for whom hemophilia A had been suspected.

Indexed as

Côte d’IvoireHemophilia Avon Willebrand type 3

Identifiers

PMID32180914
PMCPMC7059751
OpenAlexW3006707268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.